A speculative coronavirus vaccine developed by the biotech business Novavax is 89.3 percent reliable at avoiding Covid-19, the business revealed Thursday.

An interim analysis of the company’s trial in the U.K., which consisted of more than 15,000 participants ages 18 to 84, found that the vaccine was 95.6 percent efficient versus the virus and 85.6 percent efficient versus the more contagious U.K. variant.

Unlike the vaccines developed by Pfizer-BioNTech and Moderna, which use snippets of hereditary code known as messenger RNA to set off the immune system to produce protective antibodies, Novavax’s vaccine relies on synthesized coronavirus proteins to jump-start the body’s immune system.


Please enter your comment!
Please enter your name here